Ray Therapeutics is a clinical-stage biotechnology company developing optogenetic, gene-based medicines to restore vision in people with blinding degenerative retinal diseases. Its approach reprograms surviving retinal neurons to detect light and transmit visual signals to the brain, independent of the underlying gene mutation. - View it on GitHub